Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on May 3, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print May 3, 2007, doi: 10.1161/ATVBAHA.106.134114
A more recent version of this article appeared on July 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/7/1535    most recent
ATVBAHA.106.134114v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kada, N.
Right arrow Articles by Nagai, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kada, N.
Right arrow Articles by Nagai, R.
Related Collections
Right arrow Gene expression

Submitted on October 21, 2006
Accepted on April 1, 2007

Acyclic Retinoid Inhibits Neointima Formation Through Retinoic Acid Receptor Beta-Induced Apoptosis

Nanae Kada ; Toru Suzuki *; Kenichi Aizawa ; Takayoshi Matsumura ; Naoto Ishibashi ; Naomi Suzuki ; Norifumi Takeda ; Yoshiko Munemasa ; Daigo Sawaki ; Takashi Ishikawa ; and Ryozo Nagai

From the Departments of Cardiovascular Medicine (N.K., T.S., K.A., T.M., N.T., Y.M., D.S., R.N.), Clinical Bioinformatics (T.S.), and Gastroenterology (T.I.), The University of Tokyo, and Pharmaceutical Research Laboratories (N.I., N.S.), Nikken Chemicals Co, Saitama, Japan.

* To whom correspondence should be addressed. E-mail: torusuzu-tky{at}umin.ac.jp.

Objectives--Acyclic retinoid (ACR) is a synthetic retinoid with a high safety profile that has been pursued with high expectations for therapeutic use in prevention (recurrence) and treatment of malignancies. With the objective of addressing the therapeutic potential in the cardiovasculature, namely neointima formation, effects of ACR on neointima formation and the involved mechanisms were investigated.

Methods and Results--ACR was administered to cuff-injured mice which showed inhibition of neointima formation. Investigation of involved mechanisms at the cellular and molecular levels showed that ACR induces apoptosis of neointimal cells and this to be mediated by selective induction of retinoic-acid receptor {beta} (RAR{beta}) which shows growth inhibitory and proapoptotic effects on smooth muscle cells.

Conclusion--We show that ACR inhibits neointima formation by inducing RAR{beta} which in turn inhibits cell growth and induces apoptosis. The retinoid, ACR, may be potentially exploitable for treatment and prevention of neointima formation.
Key words: smooth muscle cell • cell growth • retinoid




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Zheng, M. Han, M. Bernier, X.-h. Zhang, F. Meng, S.-b. Miao, M. He, X.-m. Zhao, and J.-k. Wen
Kruppel-like Factor 4 Inhibits Proliferation by Platelet-derived Growth Factor Receptor {beta}-mediated, Not by Retinoic Acid Receptor {alpha}-mediated, Phosphatidylinositol 3-Kinase and ERK Signaling in Vascular Smooth Muscle Cells
J. Biol. Chem., August 21, 2009; 284(34): 22773 - 22785.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.